SHMT2 and neoplasm: Regarding the SHMT2 IHC data, 58 cases (65%) exhibited strong immunopositivity, 18 cases (21%) exhibited moderate immunopositivity, and 12 cases (14%) exhibited no or weak immunopositivity in tumor tissues (Figure S8B).